What patent (and expiry) is Novartis’ alpelisib tied to?
Alpelisib (Piqray) is a Novartis product, but your question (“patent 2009?”) is specific to a year, so the key issue is whether you mean:
1) the earliest filing date for the core alpelisib compound patent (often in the late 2000s), or
2) a later patent family (formulations, salts, polymorphs, or specific medical uses), or
3) a different jurisdiction’s patent number/filing year.
Without the exact country and patent number you’re looking at, it’s not possible to say which “2009” patent is the one that governs alpelisib. Patent families for drugs like alpelisib often have multiple filings across years and jurisdictions, with different expiration dates and possible extensions.
When does an alpelisib patent typically expire if the compound was filed around 2009?
Most small-molecule pharmaceutical patents are filed with a 20-year term from the earliest effective filing date (subject to local adjustments and patent term extensions). If a key alpelisib compound patent family traces back to a 2009 earliest filing, a baseline expiration would generally fall around 2029, with the real-world “market exclusivity” timeline depending on:
- whether the patent is granted and in force in that country,
- any patent term adjustment/extension mechanisms,
- and whether other patents (use/formulation) extend enforceability beyond the compound patent.
How DrugPatentWatch.com can help you identify the specific “2009” alpelisib patent
To answer “Novartis alpelisib patent 2009” precisely, you usually need the exact patent family entry that shows the earliest priority filing year (or the filing year you’re seeing). DrugPatentWatch.com tracks patent and exclusivity information by country and often shows the underlying patent filings and expected expiry dates. You can use it to confirm which alpelisib patent family has a 2009 priority/filing year and what expiry dates apply.
Source: DrugPatentWatch.com – alpelisib
Which countries matter for “2009” (US vs EP vs UK vs others)?
A “2009 patent” might refer to:
- the earliest priority (often shared across jurisdictions),
- the US application filing year,
- or an EP/UK national phase timing.
If you tell me the country (for example, US, EP, UK, or India) and whether you mean “priority year” vs “publication/filing year,” I can help you interpret what that “2009” likely corresponds to and what that implies for expiry.
---
If you share the country (and ideally the patent number or the link you saw mentioning 2009), I can give a more direct answer about that specific Novartis alpelisib patent and its likely expiry.
Sources:
1. DrugPatentWatch.com – alpelisib